Shenandoah Oncology’s recommendations regarding the COVID-19 vaccine and booster.
 Learn More

Clinical Trials

Open Trials

At Shenandoah Oncology, research is an integral part of our comprehensive efforts to provide cancer patients in our community with access to the latest and most advanced therapies and treatment options.  As a member of US Oncology Research and as a clinical research affiliate of VCU Massey Cancer Center, we are pleased to share this list of clinical trials currently enrolling at our practice.


USOR 20-210: Phase 4, Observational Breast Cancer Study for stage I-III hormone receptor-positive (HR+) breast cancer that has taken adjuvant endocrine therapy for 4-7 years. Breast Cancer Index (BCI) Registry Study.  Click here to learn more


USOR 21-380: Phase 3, double-blind, randomized, placebo-controlled study of abemaciclib + fulvestrant versus placebo + fulvestrant for patients with hormone receptor-positive, HER2 negative, who have progressed after prior treatment with CDK4 & 6 inhibitor and endocrine therapy.  Click here to learn more


A221805: Phase 2/3, randomized, double-blind, placebo-controlled study of duloxetine to prevent oxaliplatin-induced chemotherapy-induced peripheral neuropathy.  Click here to learn more


A031902: Phase 3, randomized, double-blind, placebo-controlled trial comparing enzalutamide + rucaparib vs. enzalutamide + placebo in first-line metastatic castration-resistant prostate cancer.  Click here to learn more


USOR 21-236: Detecting cancers earlier through elective plasma-based CancerSEEK testing. Patients age 50 years old or greater with untreated solid tumors will undergo one-time blood draw to obtain clinically characterized, whole blood specimens from cancer subjects to develop and refine assays for cancer in the blood.


A032001: Phase 3, randomized trial of maintenance cabozantinib & avelumab vs maintenance avelumab alone after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer.  Click here to learn more

Learn More